25
08, 2021
15
09, 2015
Valentina Guarneri et al., Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. The Oncologist
Diatech Pharmacogenetics2017-08-08T09:48:41+02:00
14
04, 2014